Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Follows up the Death of Farah Kassab and Issues Two Decisions and Two Letters to the General Prosecution and the Order of Physicians

 
The Information Office of Deputy Prime Minister Health Minister Ghassan Hasbani issued the following statement:
 
In the context of following up the death of Farah Kassab after she underwent a cosmetic surgery in a specialized hospital in cosmetic surgeries,
 
Health Minister Ghassan Hasbani took the following actions:
 
  1. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in day hospitals or other cosmetic surgery clinics.
  2. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in Dr. Nader Saab hospital specialized in cosmetic surgery.
  3. The issuance of a letter to the Public Prosecutor to investigate into the death of Farah Kassab.
  4. The issuance of a letter to the Lebanese Order of Physicians in Beirut to conduct necessary investigations into the death of Farah Kassab, and give the Order a period of two weeks to clarify some technical medical points and answer questions asked by Health Minister concerning the death of the said woman.
 
These steps came to complete the immediate oral decision of Health Minister Ghassan Hasbani to cease operations in the said clinic after the woman's death, and the written decision issued Friday 2 June 2017 which stipulates the following:
 
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not performed in places other than specialized hospitals which include an intensive care division that holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent.
    3
    ...
ATC Name B/G Ingredients Dosage Form Price
M02AA15 LOCAGEL G Diclofenac sodium (diethylamine) - 10mg/g 10mg/g Gel 223,078 L.L
D11AX18 LABDIC RELIEF G Diclofenac sodium - 1%w/w, Methyl salicylate - 8%w/w, Menthol - 2%w/w Gel 263,393 L.L
C01AA05 LANOXIN PG B Digoxin - 0.05mg/ml 0.05mg/ml Elixir 307,740 L.L
C01AA05 LANOXIN B Digoxin - 0.25mg 0.25mg Tablet 215,015 L.L
R05CA12 LIBLAB COUGH SYRUP G Dried Ivy leaf extract - 35mg/5ml 35mg/5ml Syrup 237,860 L.L
R05CA12 LIBLAB COUGH SUPPOSITORIES G Dried Ivy leaf extract - 80mg 80mg Suppository 142,447 L.L
N06AX21 LOXYT 30 G Duloxetine HCl - 30mg 30mg Capsule, delayed release 716,716 L.L
N06AX21 LOXYT 60 G Duloxetine HCl - 60mg 60mg Capsule, delayed release 831,903 L.L
B01AB05 LOVENOX BioTech Enoxaparin sodium - 2,000UI (20mg)/0.2ml 2,000UI (20mg)/0.2ml Injectable solution 467,657 L.L
B01AB05 LOVENOX BioTech Enoxaparin sodium - 4,000UI (40mg)/0.4ml 4,000UI (40mg)/0.4ml Injectable solution 886,936 L.L
B01AB05 LOVENOX BioTech Enoxaparin sodium - 6000UI (60mg)/0.6ml 6000UI (60mg)/0.6ml Injectable solution 1,085,825 L.L
B01AB05 LOVENOX BioTech Enoxaparin sodium - 8000UI (80mg)/0.8ml 8000UI (80mg)/0.8ml Injectable solution 1,206,771 L.L
C10AB05 LIPANTHYL B Fenofibrate - 160mg 160mg Tablet, film coated, modified release 1,154,238 L.L
C10AB05 LIPAFIB G Fenofibrate - 160mg 160mg Tablet 627,127 L.L
C10AB05 LIPANTHYL 200 M B Fenofibrate - 200mg 200mg Capsule 1,115,364 L.L
G01AF12 LOMEXIN "T" B Fenticonazole nitrate - 1,000mg 1,000mg Ovule 909,037 L.L
G01AF12 LOMEXIN B Fenticonazole nitrate - 200mg 200mg Ovule 810,359 L.L
D01AC12 LOMEXIN B Fenticonazole nitrate - 2g/100g 2% Cream 758,029 L.L
G01AF12 LOMEXIN B Fenticonazole nitrate - 600mg 600mg Ovule 850,727 L.L
L04AA27 LYXIA G Fingolimod Hydrochloride - 0.25mg 0.5mg Capsule, hard 32,406,715 L.L
L04AA27 LYXIA G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule, hard 32,406,715 L.L
C03CA01 LASIMIDE G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 1,300,328 L.L
C03CA01 LASIX B Furosemide - 40mg 40mg Tablet 120,946 L.L
C03CA01 LASIX B Furosemide - 500mg 500mg Tablet 1,454,038 L.L
C10AB04 LOPID B Gemfibrozil - 600mg 600mg Tablet, film coated 498,566 L.L
C10AB04 LOW-LIP G Gemfibrozil - 600mg 600mg Tablet, film coated 298,333 L.L
A10BB09 LOWZID XR G Gliclazide - 60mg 60mg Tablet, extended release 309,724 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 0.1% 0.1% Lipocream 221,734 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 0.1% 0.1% Lipocream 221,734 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 0.1% 0.1% Lotion 201,576 L.L
    3
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025